Drugs strategy review finds staff shortages and service disruption
Rural areas, young people and marginalised groups are reported as being 'disproportionately affected' by service discrepancies.
Meanwhile, the review found that annual funding arrangements and restrictive hiring policies have contributed to staff shortages and disruptions in service delivery.
The National Drug Strategy (NDS) is set out as a national framework for addressing substance use through a 'whole-of-government, person-centred, and health-led' approach that primarily frames substance use as a public health issue.
An independent review of the strategy, published today, found that several stakeholders also believe prevention efforts are underdeveloped, inconsistent and lacking national ownership.
The report compiled by Grant Thornton notes some progress and achievements but makes 10 recommendations for the future direction of the strategy.
The authors consulted with the Health Service Executive (HSE), the Health Research Board (HRB), members of the National Oversight Committee (NOC) and Strategic Implementation Groups (SIG) for the NDS, as well as service users and family members with lived experience of drug use.
Based on those engagements, it found that equity of access continues to be a concern, particularly for marginalised groups.
Prevention and early intervention efforts were found to be fragmented and inconsistently delivered, while recovery and service user involvement requires further formalisation and resourcing.
Additionally, the limited integration of alcohol policy and the 'gradual implementation of legal reforms', such as alternative sanctions, were identified as areas requiring strategic refinement.
Meanwhile, governance structures were found to lack clearly defined roles, mandates, and accountability mechanisms.
Stakeholders highlighted the need for strong national leadership, enhanced co-ordination across departments, and more inclusive decision-making processes that incorporate lived experience of service users.
Advertisement
There were also calls for enhanced data integration and the establishment of a national research and evaluation centre.
The report also details claims of inconsistent reporting from all treatment providers which is further constraining the ability to assess the strategy's effectiveness.
Stakeholders reported that high attrition rates have been observed in different regions due to factors including limited funding.
There were repeated calls by some stakeholders for multi-annual funding commitments and targeted workforce investment to support more consistent and sustainable service provision.
Prevention efforts were widely viewed as 'under-resourced and lacking strategic focus'.
There was an emphasis on the need for early, community-based interventions that address root causes, such as trauma, poverty, and social disadvantage.
Evidence shows that early life experiences significantly influence later substance use.
The SPHE programme in schools was repeatedly cited for its inconsistent delivery.
Many stakeholders also felt that the NDS lacked clarity and strategic direction regarding alcohol addiction.
The Minister for Health, Jennifer Carroll MacNeill said it is 'essential' to assess how the more than 300 million euro in annual public expenditure on drugs delivers impact.
She said: 'The establishment of new HSE health regions presents a valuable opportunity to tailor drug treatment services to population needs and to ensure that both existing and new funding is allocated effectively and transparently.'
Meanwhile, Minister of State with responsibility for the National Drugs Strategy, Jennifer Murnane O'Connor, said: 'We have made significant progress in implementing the national drugs strategy, and I'm pleased that the independent evaluation documents the many achievements over the last eight years.'
She added: 'The recommendations from the independent evaluation will inform the development of the successor National Drugs Strategy. We need to move forward with new policies and better services to address the ever-changing drugs situation.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Irish Sun
6 hours ago
- The Irish Sun
Govt walks back plans to force companies to slap health warnings on booze amid rising cost pressure & Trump tariff fears
THE Government has canned plans to force booze companies to put health warnings on beer, wine and spirits. The measure has been slapped with a two-year delay due to concerns that it would hurt Irish 3 Frank Murray of Alcohol Action Ireland said there is a huge link between cancer and alcohol consumption 3 Tainiste Simon Harris brought the motion to cabinet Credit: PA The last The law was due to kick in next year but the Cabinet today agreed to put it on the long finger following backlash by the booze businesses. Industry figures had warned the Government that the introduction of the labels specifically for Ireland would create an added cost for businesses which could have an impact on prices for consumers. This increase in cost for companies was coming at a time when Trump is threatening tariffs of up to 30 per cent on all goods travelling from READ MORE IN IRISH NEWS Many Irish beer and whiskey companies rely on the US market for major sales, and tariffs run the risk of hurting their bottom line. In a bid to ease the pressure on these companies, the Cabinet today agreed to delay the introduction of the Tanaiste The Tanaiste told his Government colleagues that the delay will enable the Most read in Irish News However, one Minister told the Irish Sun that the alcohol labelling law will not see the light of day under the current Government. They said: 'That's that done. You won't be hearing about that again.' 'PEOPLE DON'T KNOW THOSE RISKS' Alcohol Action Ireland had previously slammed the Government's decision to delay the label law. Chairperson of Alcohol Action Ireland Professor Frank Murray told 'Unfortunately, the risk of alcohol consumption in terms of cancer, for instance, begins at very low levels of alcohol consumption, particularly breast cancer. 'Again, most people don't know that I'm afraid.' NEW PLAN The The proposal comes as part of a newly published ten-year NHS plan. There have also been similar initiatives in other countries — including 3 It was proposed that booze get slapped with a health warning Credit: Getty
The Journal
10 hours ago
- The Journal
'The real work starts now': Long-awaited inquiry into drug that causes birth defects begins
A LONG-AWAITED inquiry into an antiepileptic drug that can cause serious birth defects if used during pregnancy has finally gotten underway, nearly five years after the Government committed to holding one. The non-statutory inquiry into the historical licensing and use of sodium valproate will have three strands, with statements from those affected by the drug expected to be taken from September. Health Minister Jennifer Carroll MacNeill has welcomed the commencement, saying that it 'will give those directly affected by sodium valproate an opportunity to have their voices heard'. The inquiry was approved by Cabinet in July 2023 , almost three years after the then-health minister Stephen Donnelly committed to holding a probe into the drug. Barrister and mediator Bríd Flaherty was announced as the chairperson of the non-statutory inquiry in June 2024, with Donnelly saying at the time that he intended to get it up and running ' in a matter of weeks ', but this did not take place. The delay in the commencement of the inquiry is understood to have been due to the fact that the data regulations had yet to be finalised. Sodium valproate can cause serious birth defects and developmental disorders to an infant if taken during pregnancy and women have been advised against using it unless no other treatment is possible. The drug was prescribed in Ireland and elsewhere for years after the danger was discovered and many countries are now investigating its use. Today, the Health Products Regulatory Authority (HPRA) states that the drug can cause birth defects and problems with the development and learning of the child if their mother takes it during pregnancy. Advertisement Children exposed to the drug while in the womb are at a high risk of serious developmental disorders (in up to 30-40% of cases) and congenital malformations (in approximately 10% of cases). Symptoms of fetal valproate syndrome (FVS) vary, but can include characteristic facial features, spina bifida, congenital heart defects, cleft lip and/or cleft palate, genital abnormalities, skeletal abnormalities and developmental delay. The drug's risk to infants has been made public in recent years, but campaigners in the UK found documents in the National Archives that indicated health regulators were aware of the risk as far back as 1973 but chose not to warn patients, saying it 'could give rise to fruitless anxiety'. A HSE report published in 2018 estimated that 1,250 children have been affected by valproate since 1975 in Ireland. In 2021, an investigation by The Journal Investigates found that around 3,000 Irish children were potentially harmed by exposure to the drug in the womb. Read The Journal Investigates's investigation into the valproate scandal . Last January, doctors began informing men of the potential risks that taking sodium valproate can have on their future children before prescribing it to them following precautionary measures recommended by the European Medicines Agency. Inquiry The Department of Health said the inquiry will have three strands. The first strand will be the review phase, which will establish a timeline for the use of sodium valproate in Ireland 'in women of childbearing potential including information on regulation, prescribing, dispensing and safety information issued'. The inquiry will seek to document the evolution of the regulation of the drug and the practices around the control of it. The Department said the inquiry 'will have responsibility to request documentation and submissions from a range of stakeholders', and the chair will record 'difficulties encountered where such requests are refused as part of their reporting function'. The second strand of the inquiry will seek oral statements from anyone impacted by the use of the drug, including people diagnosed with Foetal Valproate Spectrum Disorder (FVSD), their mothers and other family members who may wish to participate. This is anticipated to begin in September. Anyone who wishes to take part in this strand of the inquiry can register their interest on its website . These sessions will be held in private, and other stakeholders may also be invited to provide oral statements in separate sessions. Related Reads Chairperson appointed to probe into drug that causes birth defects after almost a year's delay Six months on, chairperson yet to be appointed to inquiry into drug that causes birth defects Doctors to inform men taking sodium valproate of risks to unborn children The third strand will focus on assessing the health service's current capacity to respond to safety issues 'related to use of anti-seizure medications (ASMs) in women of childbearing potential'. This will involve an assessment of the current systems in place to respond, disseminate and implement measures that address these potential safety issues, the development of other recommendations regarding current control systems for sodium valproate and other ASMs, and the services and supports for those impacted by sodium valproate. The Department said the results of this assessment will inform future service development. A communications campaign will be launched in the coming weeks to raise public awareness and support engagement with the inquiry. 'The real work starts now' Last month, when the inquiry had yet to commence, the Organisation for Anticonvulsant Syndromes (OACS) Ireland group, which supports families that have been impacted by the drug, told The Journal that it was seeking a meeting with the Minister for Health to discuss the status of the inquiry. Today, Carroll MacNeill said she was 'grateful' to meet with OACS Ireland recently 'and I know this is an important day for them and the families they represent'. 'I have every confidence that the Chair will conduct an independent and fair Inquiry and finally get answers for those affected and their families,' she said. In a statement, chair of OACS Ireland Karen Keely, whose three adult sons have been affected by exposure to sodium valproate, said: 'The real work starts now. 'The Inquiry will draw a spotlight on a public health issue which, whilst life-changing, is perhaps not as well known or understood by the public as other public health issues,' Keely said. Solicitor Ciara McPhillips, who represents OACS Ireland within the inquiry process, said: 'Together with OACS, I look forward to working with all stakeholders under the stewardship of the Chair to ensure those affected understand how it arose that women and mothers were prescribed a medication, which whilst very effective in preventing seizures, was so devastatingly detrimental to their children – many of whom will never live independent lives.' Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Extra.ie
20 hours ago
- Extra.ie
Cutting costs: Vasectomies could soon be free across Ireland as men urged to 'step up'
Vasectomies may soon be offered for free across the country, the Health Minister has confirmed. Jennifer Carroll MacNeill was responding to a question by Labour's Marie Sherlock TD, who told the Dáil that it was time for men to 'step up' and stop relying on women to use contraceptives. Responding to a parliamentary question from Ms Sherlock, Ms Carroll MacNeill agreed that there was 'significant inequity of access' to vasectomy, both geographically and based on ability to pay, and that the Government is now considering free access to vasectomies across the country. Jennifer Carroll MacNeill. Pic: Stephen Collins/ Collins Photos She said that the Department of Health's National Sexual Health Strategy is 'committed to scoping the potential for expanding access to male and female sterilisation', including vasectomies for men. The Minister also said that a strategy will be created 'as soon as possible in 2025.' Vasectomies are currently available without cost to some medical cardholders. Ms Sherlock told the Dáil: 'The responsibility for family planning shouldn't just fall on the woman's shoulders. There's a simple, relatively pain-free procedure that a man recovers from within a very few short hours, but obviously it has a transformative impact on the family. Marie Sherlock. Photo: RTÉ. 'We have to make sure in the whole family planning conversation that men step up and take their responsibility seriously. There's a real inequality of access to the service, and particularly outside of the main urban areas,' she said. 'There's a crucial issue here about how we encourage and incentivise doctors to take on the service, and crucially, then from the department of health perspective, that there is a decent geographical spread of these services across the country.' However, Aontú leader, Peadar Tóibín, last night questioned whether the Government should be offering free vasectomies while Ireland's fertility rates continue to plunge. Peadar Tóibín. Pic: Fran Veale Mr Tóibín said: 'There are major questions in relation to where the Government is going in relation to this. So what we've seen in the last decade is a collapse in the fertility levels. They're lower now than the replacement rate, which means there's going to be significantly fewer children in future than there were in the past.' The fertility rate for 2024 stood at 1.5, a decrease of 0.5 from the 2014 fertility rate of 2.0. This is still higher than the European average, which stands at 1.38 births per woman in the EU. In Malta, the fertility rate stands at 1.06, compared to 1.81 in Bulgaria. Mr Tóibín warned that Ireland will create 'lopsided demographics, which means there will be fewer young people to be able to work, to provide the taxes to pay the pensions for people into the future. 'Good governance means a balanced demographics, and actually, at this moment in time, that means encouraging families to have more children. 'There's no doubt that the housing crisis is hammering families. They're delaying having children, and they're living, oftentimes, young couples in their parents' box room, which means that they can't have children and it's later and later until people are getting mortgages.' He went on: 'The cost of childcare is prohibitive for many, many people, and also the abortion rates have increased from about 3,000 abortions a year in 2018 to spiking well over 10,000 now.' 'All of these issues are pushing down the number of children that have been born. We should be giving families the economic confidence to be able to raise their children, to be able to have children, and so that we have a vibrant society and economy into the future.' Ryan Murphy, the operations manager at Sandyford, Dublin-based clinic said that vasectomies could not be accessed in multiple areas of the country, creating a 'two-tier system'.
